Advanced HER2-Positive Gastric Cancer

Applying Clinical Evidence in Advanced HER2-Positive Gastric Cancer

Advanced HER2-Positive Gastric Cancer

Tune in to learn more about the role of HER2 as an oncogenic driver in gastric cancers and advances in targeting HER2 for interventional therapy.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Do you face clinical challenges when managing patients with advanced HER2-positive gastric cancer? You’re not alone. Advanced gastroesophageal cancers remain among the most difficult cancers for clinicians to manage. One of the many challenges to optimizing patient outcomes is a relative lack of familiarity with practice standards regarding HER2-positive disease. While HER2 is an oncogenic driver in gastroesophageal cancers, it does not appear to act as a predictive biomarker in quite the same way as it does in breast cancer. However, there are ways to fully optimize anti-HER2 therapy in gastroesophageal cancers. Join us as Dr. Daniel Catenacci and Dr. Yelena Janjigian demystify HER2-positive gastroesophageal cancers and provide insights for the integration of personalized therapeutic approaches for these patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Daniel Catenacci, MD
    Associate Professor
    University of Chicago
    Chicago, IL 

    No relevant relationships to disclose at this time.

    Yelena Janjigian, MD
    Chief, Gastrointestinal Oncology Service
    Memorial Sloan Kettering Cancer Center
    New York, NY 

    Consulting Fees and Travel Funding: Daiichi Sankyo, AstraZeneca

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry Fiedel, PhD, has nothing to disclose.
    • Anna Trentini has nothing to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe how issues surrounding HER2 testing impact subsequent therapy selection in patients with advanced gastric cancer
    • Interpret the latest clinical data on treatment resistance for HER2-positive advanced gastric cancer
    • Apply clinical data in developing a personalized treatment plan for patients with HER2-positive advanced gastric cancer
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, and gastroenterologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    ReachMD Healthcare Image

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Daiichi Sankyo and AstraZeneca.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free